Gustavo Vasconcelos Alves

机构：Hospital de Clínicas de Porto Alegre, Hospital Nossa Senhora da Conceição · ORCID：0000-0003-4985-5555

发表论文 52 篇 · 总被引 2117 次 · h-index 12

代表论文

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 661)
• Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer (2025 · New England Journal of Medicine · 被引 325)
• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial (2024 · The Lancet Oncology · 被引 223)
• RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 37)
• Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC). (2025 · Journal of Clinical Oncology · 被引 12)
• Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study. (2025 · Journal of Clinical Oncology · 被引 10)